Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd > Will Pfizer & Revive work to develop and commercialize Buc ?

<< Previous

Bullboard Posts

Next >>

Comment by SmartPodhotzoneon Dec 28, 2020 6:33pm

87 Views

Post# 32188841

RE:Will Pfizer & Revive work to develop and commercialize Buc ?

More like vaccines from majors will Take this pump and dump to zero

cool888 wrote: Just a thought..... anything is possible..... comments are always appreciated !!!
Myovant Shares Surge on Collaboration With Pfizer

Shares of Myovant Sciences Ltd. rose more than 30% on Monday after the biopharmaceutical company inked a collaboration potentially worth more than $4 billion with Pfizer Inc.

Under the deal, the companies will work to develop and commercialize Myovant's relugolix in oncology and women's health in the U.S. and Canada.

Myovant said it will receive an upfront payment of $650 million, along with potential regulatory and sales milestones, for a total payment of up to $4.2 billion.

Myovant earlier this year received U.S. Food and Drug Administration approval of relugolix, to be marketed as Orgovyx, for the treatment of adults with advanced prostate cancer.

The agency is currently reviewing a relugolix combination tablet for women with uterine fibroids, with a target action date of June 1, 2021. Myovant also is developing the combination tablet for women with endometriosis.

Myovant shares were recently up 30.3% to $29.65.